Timothy Schmid Sells 1,322 Shares of Johnson & Johnson (NYSE:JNJ) Stock

Johnson & Johnson (NYSE:JNJ) EVP Timothy Schmid sold 1,322 shares of the stock in a transaction on Friday, February 20th. The stock was sold at an average price of $245.66, for a total value of $324,762.52. Following the sale, the executive vice president owned 25,447 shares in the company, valued at $6,251,310.02. The trade was a 4.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Timothy Schmid also recently made the following trade(s):

• On Wednesday, February 18th, Timothy Schmid sold 22,623 shares of Johnson & Johnson stock. The shares were sold at an average price of $244.33, for a total value of $5,527,477.59.

Johnson & Johnson Stock Up 0.2%

Shares of NYSE:JNJ opened at $246.21 on Wednesday. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.48. The firm has a market cap of $593.35 billion, a P/E ratio of 22.28, a P/E/G ratio of 2.39 and a beta of 0.35. Johnson & Johnson has a 12 month low of $141.50 and a 12 month high of $247.25. The company’s 50-day moving average price is $222.42 and its two-hundred day moving average price is $200.48.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. The company had revenue of $24.28 billion during the quarter. As a group, research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 47.06%.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Regulatory/clinical catalyst — J&J submitted an sBLA for IMAAVY (nipocalimab) seeking the first FDA‑approved therapy for warm autoimmune hemolytic anemia, supported by positive pivotal ENERGY trial results; an approval would add a new, high‑value orphan indication. Johnson & Johnson seeks FDA approval of IMAAVY (PR Newswire)
• Positive Sentiment: Strategic growth story — coverage notes J&J’s pivot to high‑margin MedTech, strong oncology momentum (Darzalex) and Tremfya data, and a roadmap to ~$100B revenue — a narrative that supports multiple buyers seeking defensive growth and yield. Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector
• Positive Sentiment: Clinical durability for key immunology franchise — new three‑year TREMFYA ulcerative colitis data showing sustained outcomes bolsters confidence in J&J’s ability to offset older drug losses with high‑growth franchises. Johnson & Johnson presents three-year TREMFYA data (MSN)
• Neutral Sentiment: Dividend mechanics — the stock recently went ex‑dividend (quarterly $1.30), a technical event that can create short‑term price movement unrelated to fundamentals; income investors may view dips as buying opportunities. Boring Is Beautiful: Why Johnson & Johnson Is Beating the Tech Sector
• Neutral Sentiment: Mixed market signals — analyst notes and options activity are generally upbeat but varied; some price targets have been raised while other coverage is cautious, so near‑term volatility may persist. Wall Street Bulls Look Optimistic About Johnson & Johnson (Zacks)
• Negative Sentiment: Legal overhang — Bayer filed a lawsuit against J&J/Janssen over marketing claims tied to a prostate cancer drug, introducing potential reputational and litigation risk for the biotech unit (timing and financial exposure are uncertain). Bayer files lawsuit against Johnson & Johnson, Janssen Biotech (Reuters)
• Negative Sentiment: Insider selling — EVP Timothy Schmid disclosed recent sales (Form 4 filings), which some investors interpret as profit‑taking and can weigh on sentiment despite being routine. SEC filing: Form 4 (Insider Sale)

Wall Street Analyst Weigh In

JNJ has been the subject of several recent research reports. Wolfe Research upped their target price on shares of Johnson & Johnson from $225.00 to $240.00 and gave the company an “outperform” rating in a research report on Monday, January 5th. UBS Group reiterated a “buy” rating on shares of Johnson & Johnson in a report on Monday, January 5th. Royal Bank Of Canada increased their target price on Johnson & Johnson from $240.00 to $255.00 and gave the company an “outperform” rating in a research note on Tuesday, February 3rd. Guggenheim boosted their target price on Johnson & Johnson from $227.00 to $240.00 and gave the stock a “buy” rating in a research report on Friday, January 23rd. Finally, Bank of America increased their price target on shares of Johnson & Johnson from $220.00 to $221.00 and gave the company a “neutral” rating in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $232.70.

Hedge Funds Weigh In On Johnson & Johnson

Several institutional investors have recently modified their holdings of the business. Blueline Advisors LLC bought a new stake in shares of Johnson & Johnson during the fourth quarter worth $25,000. Abich Financial Wealth Management LLC acquired a new position in Johnson & Johnson in the 3rd quarter worth $26,000. Cresta Advisors Ltd. bought a new position in Johnson & Johnson during the 4th quarter worth about $26,000. Evolution Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $27,000. Finally, Clayton Financial Group LLC bought a new stake in shares of Johnson & Johnson in the third quarter valued at about $28,000. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.